JNJ

Johnson & Johnson

$270.47

+1.25%
Nov 20, 2026
Bobby Quantitative Model
Johnson & Johnson is the world's largest diversified healthcare company, operating through two segments following the 2023 spin-off of its consumer business, Kenvue: Innovative Medicine (pharmaceuticals focused on immunology, oncology, and neurology) and MedTech (surgical, orthopedic, and interventional devices), with just over half of revenue generated in the United States. J&J's competitive identity rests on scale, balance-sheet strength, and a AAA-grade dividend franchise — a 64-year streak of annual increases — that positions it as a defensive core healthcare holding rather than a high-growth disruptor. The current investor narrative centers on the company's raised full-year sales outlook and a path toward $100 billion in annual revenue, driven by booming oncology franchises, even as it absorbed roughly $7 billion in one-time charges tied to litigation and strategic restructuring in the most recent quarter. Debate now hinges on whether the Innovative Medicine growth engine can outrun MedTech headwinds, Stelara biosimilar erosion, and persistent talc/legal overhangs — a tension reflected in the stock's powerful 2026 re-rating alongside analyst caution on near-term margin optics.

People also watch

Eli Lilly and Company

Eli Lilly and Company

LLY

Analysis
AbbVie

AbbVie

ABBV

Analysis
Merck & Co.

Merck & Co.

MRK

Analysis
Amgen

Amgen

AMGN

Analysis
Gilead Sciences

Gilead Sciences

GILD

Analysis

BobbyInvestment Opinion: Should I buy JNJ Today?

Rating: Hold (with a constructive, accumulate-on-weakness bias). The core thesis is that J&J remains a high-quality defensive compounder whose oncology-led Innovative Medicine franchise is reaccelerating revenue at 5.86% YoY, but at $285.75 the stock has already run 46.35% over one year and now trades roughly 2.2% above the $279.41 average analyst target despite a consensus 'buy' rating (mean 1.91, 16 Buy / 6 Hold / 1 Sell). In short, the business quality justifies ownership, but the current entry price does not offer a compelling margin of safety.

Supporting evidence is genuinely strong: normalized consensus EPS of $17.44 implies only about 16.4x earnings against a PEG of 0.212, gross margins of 67.88% and operating margins of 27.17% sit well above the 15-17x-typical pharma peer set, and $20.59 billion of trailing free cash flow comfortably funds $3.227 billion of quarterly dividends at a 46.19% payout ratio, underpinning the 64-year increase streak and 2.46% yield. Revenue has climbed sequentially for four straight quarters ($24.062B to $25.399B), with Innovative Medicine at $16.757 billion (~66% of sales) doing the heavy lifting, and the balance sheet is fortress-grade at 0.588 debt-to-equity with a 32.87% ROE. The catch is that the trailing 18.82x PE understates the price — the forward PE of 24.59x exceeds it, and price-to-book at 6.18x sits near the top of its 4.7x-8.2x band, meaning the market has already paid forward for the charge-driven earnings recovery.

Three risks could invalidate the thesis: Stelara biosimilar erosion outpacing oncology offsets, an adverse talc litigation outcome (the $5.811 billion other-income swing already erased Q3 net income down to $210 million), and multiple compression from 24.59x forward toward historical norms. This Hold would upgrade to Buy on a pullback toward the $250-$260 consolidation zone (roughly -9% to -13%) or on evidence that Innovative Medicine growth is sustainably outrunning Stelara erosion with clean margins; it would downgrade to Sell if revenue growth decelerates below ~3%, if MedTech deteriorates further, or if litigation produces a materially adverse judgment. Valuation verdict: fairly valued to modestly rich relative to its own history and at a premium to pharma peers — a reasonable long-term core holding, but not a bargain at current levels.

Sign up to view all

JNJ 12-Month Price Forecast

The forward view is balanced: J&J's fundamentals are solid and improving, with revenue reaccelerating, oncology-led Innovative Medicine carrying two-thirds of sales, $20.59 billion of free cash flow self-funding a 64-year dividend streak, and normalized earnings at roughly 16.4x. But the stock has already re-rated 46.35% in a year and now sits above the $279.41 consensus target with a forward PE of 24.59x above the trailing 18.82x, leaving little valuation cushion and a wide $190-$320 target range that signals genuine disagreement about terminal value. The base case (55% probability) is consolidation in the $270-$290 zone as the re-rating is digested, with a 25% bear case weighted toward Stelara erosion and litigation and a 20% bull case requiring clean execution plus legal resolution. I would upgrade to bullish on a pullback into the $250-$260 support zone or on evidence that Innovative Medicine growth is sustainably outrunning Stelara erosion with clean margins; I would downgrade to bearish if revenue growth decelerates below ~3%, MedTech deteriorates further, or litigation produces a materially adverse outcome.

Historical Price
Current Price $270.47
Average Target $280.00
High Target $320.00
Low Target $190.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $279.85 and implied upside of +3.5% versus the current price.

Average Target

$279.85

23 analysts

Implied Upside

+3.5%

vs. current price

Analyst Count

23

covering this stock

Price Range

$190 - $320

Analyst target range

Buy
16 (70%)
Hold
5 (22%)
Sell
2 (9%)

Coverage is broad and institutional, with 22 analysts contributing a consensus recommendation of "buy" (mean rating 1.91 on a 1-5 scale) and a distribution of 16 Buy, 6 Hold, and 1 Sell — a moderately bullish tilt with meaningful caution embedded. The average target price of $279.41 actually sits slightly below the current $285.75, implying roughly -2.2% downside to consensus, a notable signal that the stock has run past the average analyst's fair value estimate after its 46% one-year rally. This disconnect suggests analysts have been chasing price rather than leading it, and the recent institutional ratings flow — Wells Fargo, Morgan Stanley, RBC, Leerink, Guggenheim, Citigroup, and HSBC all reiterating Overweight/Buy/Outperform in October 2026, with JP Morgan maintaining Neutral — shows firms holding their constructive stances without aggressively raising targets. The target range is wide, from a low of $190.00 to a high of $320.00, a spread of roughly 68% of the current price that signals genuine disagreement about the company's trajectory. The high target of $320 implies approximately 12% upside and likely assumes multiple expansion on accelerating oncology growth, successful pipeline readouts, and resolution of legal overhangs; the low target of $190 (roughly 33% below current) prices in margin compression from Stelara biosimilar erosion, MedTech weakness, and adverse litigation outcomes. Consensus EPS estimates of $17.44 (range $17.18-$17.75) and revenue estimates of $135.2 billion (range $133.7-$137.1 billion) are tightly clustered, indicating high confidence in near-term fundamentals even as price targets diverge — a pattern that typically reflects disagreement over terminal value and risk rather than current-quarter execution.

Drowning in data?

Find the real signal!

Bulls vs Bears: JNJ Investment Factors

The bull case currently holds the stronger evidence: revenue is reaccelerating at 5.86% with oncology-led Innovative Medicine at 66% of sales, normalized earnings of roughly $17.44 imply only ~16.4x, free cash flow of $20.59 billion self-funds a 64-year dividend streak, and a 0.20 beta delivered 46% one-year returns with a max drawdown under 11%. The bear case is primarily about price and timing rather than business quality — the stock trades above its $279.41 consensus target, the forward PE of 24.59x exceeds the trailing 18.82x, and the $190 low target shows real disagreement about terminal value. The single most important tension is whether Innovative Medicine growth can outrun Stelara biosimilar erosion and MedTech softness fast enough to justify a multiple that has already re-rated; resolution of that question, plus the talc litigation, will determine whether the 46% rally extends or mean-reverts. On balance, the fundamentals support a constructive stance, but the risk/reward at $285.75 is far less attractive than it was at the 52-week low of $195.90.

Bullish

  • Fortress balance sheet, elite returns: Debt-to-equity of just 0.588, $20.59 billion in trailing free cash flow, and a 32.87% ROE underpin one of the strongest financial profiles in large-cap healthcare. Q3 operating cash flow of $7.72 billion comfortably covered $1.362 billion of capex and $3.227 billion of dividends, meaning the 64-year dividend increase streak is self-funded even in a charge-heavy quarter.
  • Revenue reaccelerating, oncology-led: Q3 2026 revenue of $25.399 billion grew 5.86% year-over-year and marked a fourth consecutive sequential increase from $24.062 billion in Q1. Innovative Medicine contributed $16.757 billion, roughly 66% of sales, confirming the pharmaceutical franchise — particularly oncology and immunology — is the growth engine behind the path toward $100 billion in annual revenue.
  • Normalized valuation is undemanding: The 18.82x trailing PE is distorted by one-time charges; on consensus EPS of $17.44 the stock trades near 16.4x, with a PEG of 0.212. That is a modest multiple for a franchise with high-single-digit earnings growth, 67.88% gross margins, and a 2.46% dividend yield, and it sits mid-range versus J&J's historical 9x-36x band.
  • Defensive momentum with minimal beta: JNJ is up 46.35% over one year and 37.81% YTD versus the S&P 500's 12.27% and 10.62%, with relative strength of +34.08 points over twelve months. A beta of 0.20 and max drawdown of only -10.96% mean that outperformance came from fundamental re-rating, not leverage to market risk — and the stock gained 12.54% in the past month while SPY fell 2.26%.

Bearish

  • Price has run past consensus target: At $285.75, JNJ trades above the $279.41 average analyst target, implying roughly -2.2% downside to consensus even with a 'buy' rating (mean 1.91). That disconnect after a 46% one-year rally suggests analysts are chasing price rather than leading it, and October reiterations from Wells Fargo, Morgan Stanley, RBC, and others came without aggressive target raises.
  • Forward multiple exceeds trailing: The forward PE of 24.59x is higher than the trailing 18.82x — an unusual inversion that means the market is already paying up for the expected earnings recovery as charges roll off. If that recovery disappoints, there is little valuation cushion at 6.18x price-to-book (upper end of its 4.7x-8.2x band) and 7.20x EV/Sales.
  • Stelara erosion and MedTech drag: Innovative Medicine's growth must outrun biosimilar erosion of Stelara, while MedTech at $8.642 billion is the slower-growing, stabilizing segment rather than a second engine. The $190 low analyst target — roughly 33% below the current price — explicitly prices in margin compression from Stelara biosimilars and MedTech weakness.
  • Legal overhang remains unresolved: The roughly $7 billion in one-time charges tied to litigation and restructuring in Q3 show the talc/legal overhang is still a live cash and headline risk. A $5.811 billion negative swing in other income/expenses wiped out nearly the entire quarter's net income, demonstrating how quickly legal outcomes can distort reported results and sentiment.

JNJ Technical Analysis

J&J is in a pronounced, sustained uptrend, with the stock up 46.35% over the past year and 37.81% year-to-date, dramatically outpacing the S&P 500's 12.27% and 10.62% respective gains. At $285.75, the stock is trading at approximately 97.2% of its 52-week range (low $195.90 to high $288.11), sitting just below its highs — a positioning that signals strong momentum but also raises the risk of near-term overextension and profit-taking. This is a stock in price discovery mode near all-time highs, not a value recovery play. Recent momentum is accelerating rather than fading: the stock gained 12.54% over the past month and 9.76% over three months, with the one-month move actually outpacing the three-month trend, indicating buyers are stepping in more aggressively. Relative strength versus SPY is striking — +14.80 percentage points over one month and +34.08 points over one year — while the broader market fell 2.26% over the past month, underscoring J&J's role as a defensive haven in a rotating tape. The 6-month gain of 26.04% confirms the move is broad-based rather than a single-quarter spike. Key technical levels are well defined: immediate resistance sits at the 52-week high of $288.11, roughly 0.8% above the current price, and a clean breakout above that level would confirm the uptrend and likely invite momentum and index-driven flows. Support rests at the 52-week low of $195.90, though nearer-term support is more realistically in the $250-$260 zone where the stock consolidated in September and October. The beta of 0.20 is the critical risk-management datapoint — J&J moves at roughly one-fifth the volatility of the market, meaning position sizing can be larger for equivalent risk budget, but also that the stock's outsized 46% one-year gain reflects genuine fundamental re-rating rather than beta-driven amplification. The maximum drawdown of just -10.96% over the period reinforces the low-volatility, defensive character of the name.

Beta

0.20

0.20x market volatility

Max Drawdown

-11.0%

Largest decline past year

52-Week Range

$200-$290

Price range past year

Annual Return

+33.2%

Cumulative gain past year

PeriodJNJ ReturnS&P 500
1m+4.9%-9.7%
3m+0.1%-9.9%
6m+15.4%-7.5%
1y+33.2%+4.7%
ytd+30.4%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

JNJ Fundamental Analysis

Revenue is growing steadily and reaccelerating: Q3 2026 revenue of $25.399 billion rose 5.86% year-over-year versus $23.993 billion in Q3 2025, extending a sequential climb from $24.062 billion in Q1 and $25.310 billion in Q2 2026. Segment data shows Innovative Medicine at $16.757 billion (roughly 66% of sales) versus MedTech at $8.642 billion, confirming that the pharmaceutical franchise — particularly oncology and immunology — is the primary growth engine while MedTech contributes a slower-growing but stabilizing base. The trajectory from $22.520 billion in Q4 2024 to $25.399 billion in Q3 2026 implies a mid-single-digit compounding rate consistent with consensus revenue estimates of approximately $135.2 billion, supporting the narrative of a durable, low-cyclicality growth profile rather than a hyper-growth story. Profitability is robust at the operating line but optically distorted at the net line: Q3 2026 gross margin was 68.12% (gross profit $17.302 billion) and operating income was $5.845 billion at a 23.01% operating margin, yet net income collapsed to just $210 million (EPS $0.0858) due to a $5.811 billion swing in other income/expenses tied to one-time charges. The prior three quarters were far cleaner — Q2 2026 net income of $5.534 billion (21.86% net margin), Q1 2026 $5.235 billion (21.76%), and Q4 2025 $5.116 billion (20.83%) — demonstrating that the underlying business generates consistent low-20s net margins, with gross margins holding in the 66-68% band across the trailing four quarters. The Q3 charge is the key analytical point: it is largely non-recurring, and management's decision to raise guidance despite it signals confidence in core earnings power. Balance sheet and cash generation remain fortress-like: trailing free cash flow is $20.59 billion, debt-to-equity is a conservative 0.588, and return on equity is an exceptional 32.87% (though this is flattered by a relatively thin equity base and buybacks). Liquidity is adequate but not lavish — a current ratio of 1.028 and quick ratio near 0.74 reflect the capital-intensive, acquisition-active nature of the business, while Q3 operating cash flow of $7.72 billion comfortably funded $1.362 billion of capex and $3.227 billion of dividends. The dividend payout ratio of 46.19% and 2.46% yield leave ample room for the 64-year increase streak to continue, and the company's ability to self-fund R&D ($4.652 billion in Q3 alone) plus bolt-on M&A without external financing underscores minimal financial risk.

Quarterly Revenue

$25.4B

2026-09

Revenue YoY Growth

+5.9%

YoY Comparison

Gross Margin

68.1%

Latest Quarter

Free Cash Flow

$20.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Innovative Medicine
MedTech

Open an Account, get $2 TSLA now!

Valuation Analysis: Is JNJ Overvalued?

Because J&J is solidly profitable on a trailing basis (net income positive), the PE ratio is the appropriate primary metric; the trailing PE of 18.82x versus a forward PE of 24.59x presents an unusual inversion where the forward multiple exceeds the trailing multiple, reflecting the depressed trailing earnings base caused by the Q3 one-time charges rather than genuine earnings deterioration. On normalized earnings — consensus EPS of approximately $17.44 — the stock trades at roughly 16.4x, a modest multiple for a franchise with high-single-digit earnings growth potential, and the PEG ratio of 0.212 is strikingly low, suggesting the market is not yet fully pricing in expected growth. The gap between trailing and forward multiples implies the market expects a sharp earnings recovery as charges roll off, consistent with management's raised guidance. Against sector benchmarks, J&J's 18.82x trailing PE and 5.35x PS sit at a modest premium to the broad pharmaceutical industry average (typically 15-17x), but its 67.88% gross margin, 27.17% operating margin, and 28.46% net margin are well above industry norms, justifying the premium. The 6.18x price-to-book and 7.20x EV/Sales are elevated relative to J&J's own history, while the 12.97x EV/EBITDA is reasonable for a large-cap medtech-pharma hybrid. Historically, J&J's PE has ranged from roughly 9x to 36x over the past several years, with the current 18.82x sitting near the middle of that band — neither stretched nor cheap. However, the PS ratio of 5.35x is near the lower end of its multi-year range (which has touched 26x in distorted quarters), and the PB of 6.18x is toward the upper end of its 4.7x-8.2x recent band, suggesting the market is pricing in solid but not euphoric expectations. The combination of a mid-teens normalized PE, a sub-0.25 PEG, and a 2.46% dividend yield frames JNJ as reasonably valued for a defensive compounder rather than either a bargain or an overextended momentum name.

PE

18.8x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 17x~36x

vs. Industry Avg

18.6x

Industry PE ~18.6x*

EV/EBITDA

13.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on earnings quality and concentration. Q3 2026 net income collapsed to $210 million (EPS $0.0858) from a $5.811 billion negative swing in other income/expenses, showing how legal and restructuring charges can erase a quarter's profit despite a 23.01% operating margin and $5.845 billion of operating income. Innovative Medicine at $16.757 billion represents roughly 66% of the $25.399 billion revenue base, so Stelara biosimilar erosion and any oncology or immunology setback hit two-thirds of the company directly, while MedTech at $8.642 billion offers only a stabilizing, slower-growth offset. Liquidity is adequate but not lavish — a current ratio of 1.028 and quick ratio near 0.74 — and the 46.19% payout ratio, while comfortable against $20.59 billion of trailing free cash flow, leaves less room if charges recur. Market and competitive risks are dominated by valuation compression after a 46.35% one-year and 37.81% YTD rally that far outpaced the S&P 500's 12.27% and 10.62%. The stock trades at $285.75, above the $279.41 average analyst target, with a forward PE of 24.59x exceeding the trailing 18.82x and price-to-book at 6.18x near the top of its 4.7x-8.2x band — leaving little cushion if growth decelerates. The 0.20 beta limits market-driven drawdowns but also means the rally reflects a fundamental re-rating that can reverse; the wide $190-$320 target range (a 68% spread) signals genuine disagreement, and competitive pressure from rivals such as Bristol Myers Squibb's advancing oncology pipeline and Bayer's resilient pharma division keeps the Innovative Medicine franchise contested. The worst-case scenario combines Stelara erosion faster than oncology offsets, MedTech weakness, an adverse talc litigation outcome, and multiple compression from 24.59x forward toward the low end of history. In that chain, the stock could retrace toward the $190 low analyst target, roughly -33% from $285.75, or at minimum toward the $195.90 52-week low, about -31%; a milder de-rating to the $250-$260 September-October consolidation zone would still cost roughly -9% to -13%. Given the -10.96% max drawdown over the past period, a 30%+ decline would be an extreme but not unprecedented outcome for a name that has already priced in a great deal of good news.

FAQ

The most severe risk is legal and earnings-quality related: roughly $7 billion in one-time charges, including a $5.811 billion other-income swing, already erased Q3 net income down to $210 million, and an adverse talc judgment could add further charges and headline pressure. Second is franchise concentration — Innovative Medicine at $16.757 billion is about 66% of the $25.399 billion revenue base, so Stelara biosimilar erosion or an oncology/immunology setback hits two-thirds of the company directly, while MedTech at $8.642 billion is only a stabilizing offset. Third is valuation compression: after a 46.35% one-year rally, the forward PE of 24.59x exceeds the trailing 18.82x and the stock sits above the $279.41 consensus target, leaving little cushion if growth decelerates below ~3%. Fourth is competitive pressure from rivals such as Bristol Myers Squibb's advancing oncology pipeline and Bayer's resilient pharma division, plus thin liquidity with a current ratio of 1.028 and quick ratio near 0.74.

The 12-month outlook splits into three scenarios. The base case (55% probability) targets $270-$290, assuming EPS of $17.44 on revenue of $135.2 billion with mid-single-digit growth and clean margins as charges roll off, leaving the stock to consolidate around the $279.41 average target. The bull case (20% probability) targets $310-$320, requiring oncology and immunology to outrun Stelara erosion, MedTech stabilization, and a contained talc resolution that lets the market apply a premium multiple. The bear case (25% probability) targets $190-$250, driven by faster Stelara erosion, MedTech weakness, and an adverse litigation outcome that compresses the multiple from 24.59x forward toward historical norms. The base case is most likely, and its key assumption is that the roughly $7 billion of charges prove non-recurring while Innovative Medicine growth holds near its current pace.

The answer depends on which earnings base you use, and that ambiguity is central to the debate. The trailing PE of 18.82x is distorted upward by the Q3 one-time charges that cut net income to $210 million, while the forward PE of 24.59x exceeds the trailing figure — an unusual inversion implying the market is already paying for the expected earnings recovery. On normalized consensus EPS of $17.44, the stock trades near 16.4x with a PEG of just 0.212, which looks modest for a franchise with high-single-digit growth and 67.88% gross margins. Against its own history (roughly 9x-36x), 18.82x sits mid-range, but price-to-book at 6.18x is near the top of its 4.7x-8.2x band and the stock is above the $279.41 consensus target. The verdict is fairly valued to modestly rich — the market is pricing in a clean earnings recovery and continued oncology-led growth, not a bargain.

From a risk/reward standpoint, JNJ is a good business at a less-than-ideal entry price. The fundamentals are strong — 5.86% revenue growth, 67.88% gross margins, $20.59 billion of free cash flow, a 0.588 debt-to-equity ratio, and a 2.46% dividend yield — but at $285.75 the stock trades about 2.2% above the $279.41 average analyst target despite a 'buy' consensus (16 Buy / 6 Hold / 1 Sell), meaning the 46.35% one-year rally has already captured much of the near-term upside. The biggest downside risk is a combination of Stelara biosimilar erosion, MedTech softness, and an adverse talc outcome, which the $190 low target prices at roughly -33%. JNJ is therefore a reasonable buy for long-term, income-focused investors seeking low-volatility healthcare exposure, particularly on a pullback toward the $250-$260 consolidation zone, but it offers a thin margin of safety for anyone buying at current all-time-high levels.

JNJ is structurally a long-term holding, not a trading vehicle. Its 0.20 beta and -10.96% max drawdown mean it moves at roughly one-fifth the market's volatility, so short-term price swings offer limited trading opportunity, while its 2.46% dividend yield, 46.19% payout ratio, and 64-year increase streak reward patient ownership with compounding income. The business is in a mature, mid-single-digit growth phase (5.86% YoY) with high earnings visibility from tightly clustered consensus estimates ($17.44 EPS, range $17.18-$17.75), which suits multi-year holders rather than momentum traders. That said, the stock's 12.54% one-month gain and position at 97.2% of its 52-week range ($195.90-$288.11) argue against chasing at current levels. A minimum holding period of three to five years is appropriate, ideally entered on a pullback toward the $250-$260 support zone.